Skip to Content

Arrowhead Pharmaceuticals Inc ARWR

Morningstar Rating
$24.70 −0.98 (3.82%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ARWR is trading at a 27% discount.
Price
$25.60
Fair Value
$37.42
Uncertainty
Very High
1-Star Price
$33.33
5-Star Price
$53.78
Economic Moat
Wqg
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ARWR is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$25.68
Day Range
$24.4725.50
52-Week Range
$20.6742.48
Bid/Ask
$24.21 / $24.90
Market Cap
$3.06 Bil
Volume/Avg
856,153 / 1.4 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
14.97
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
525

Comparables

Valuation

Metric
ARWR
AVIR
ALNY
Price/Earnings (Normalized)
Price/Book Value
17.020.57
Price/Sales
14.9710.65
Price/Cash Flow
208.50
Price/Earnings
ARWR
AVIR
ALNY

Financial Strength

Metric
ARWR
AVIR
ALNY
Quick Ratio
3.4617.862.86
Current Ratio
3.7318.243.08
Interest Coverage
−14.29−3.36
Quick Ratio
ARWR
AVIR
ALNY

Profitability

Metric
ARWR
AVIR
ALNY
Return on Assets (Normalized)
−28.28%−15.46%−5.60%
Return on Equity (Normalized)
−69.29%−16.16%
Return on Invested Capital (Normalized)
−50.13%−19.92%−16.93%
Return on Assets
ARWR
AVIR
ALNY
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRXlfdmlkpcPzmwt$558.5 Bil
VRTX
Vertex Pharmaceuticals IncNjhcmcbyHfkkmx$103.4 Bil
REGN
Regeneron Pharmaceuticals IncGwqkhgnHgrntgn$102.8 Bil
MRNA
Moderna IncPvclnwvdJmk$41.0 Bil
ARGX
argenx SE ADRYdrvjzdjfCvzm$22.8 Bil
BNTX
BioNTech SE ADRZpvrzsmqTzq$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncLszmyxmdrCpkxcph$18.8 Bil
BMRN
Biomarin Pharmaceutical IncTmbmcbtnQdbkvp$17.4 Bil
RPRX
Royalty Pharma PLC Class ANmbxczsncQtxlxj$12.6 Bil
INCY
Incyte CorpLcmbvvtTvgdyw$12.4 Bil

Sponsor Center